Indeed, preclinical data support the argument that NSCLC cell lines with PIK3CA or STK11 and KRAS mutation show increased sensitivity to PIK3 inhibitors or MAPK and mTOR signalling inhibition, respectively [29]-[30]. Here, PIK3CA is linked to non-small cell lung carcinoma.